The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes

References

• Wood W C, Budman D R, Korzun A H, Cooper M R, Younger J, Hart R D, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253–1259
   PubMed Web of Science ®Google Scholar
• Savarese D M, Hsieh C, Stewart F M. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997; 15: 2981–2995
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332: 901–906
   PubMed Web of Science ®Google Scholar
• Wallace E L, Churchill W H, Surgenor D M, An J, Cho G, McGurk S, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35: 802–812
   PubMed Web of Science ®Google Scholar
• Sweeney J, Headon A. Medical Intelligence Unit: Clinical Benefits of Leukodepleted Blood Products. Book. R. G. Landes, Austin, TX 1995
   Google Scholar
• Cairo M S. Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology (Williston Park) 2000; 14: 21–31
   PubMedGoogle Scholar
• Paul S R, Bennett F, Calvetti J A, Kelleher K, Wood C R, O'Hara R M, Jr, et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 1990; 87: 7512–7516
   PubMed Web of Science ®Google Scholar
• Musashi M, Yang Y C, Paul S R, Clark S C, Sudo T, Ogawa M. Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA 1991; 88: 765–769
   PubMed Web of Science ®Google Scholar
• Hirayama F, Shih J P, Awgulewitsch A, Warr G W, Clark S C, Ogawa M. Clonal proliferation of murine lymphohemopoietic progenitors in culture. Proc Natl Acad Sci USA 1992; 89: 5907–5911
   PubMed Web of Science ®Google Scholar
• Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992; 79: 327–331
   PubMed Web of Science ®Google Scholar
• Bruno E, Briddell R A, Cooper R J, Hoffman R. Effects of recombinant interleukin 11 on human megakaryocyte progenitor cells. Exp Hematol 1991; 19: 378–381
   PubMed Web of Science ®Google Scholar
• Du X, Williams D A. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997; 89: 3897–3908
   PubMed Web of Science ®Google Scholar
• Chang M, Suen Y, Meng G, Buzby J S, Bussel J, Shen V, et al. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood 1996; 88: 3354–3362
   PubMed Web of Science ®Google Scholar
• Neben S, Donaldson D, Sieff C, Mauch P, Bodine D, Ferrara J, et al. Synergistic effects of interleukin-11 with other growth factors on the expansion of murine hematopoietic progenitors and maintenance of stem cells in liquid culture. Exp Hematol 1994; 22: 353–359
   PubMed Web of Science ®Google Scholar
• Goldman S, Loebelanz J, McCarthy K, Hayes L, Neben T, Stoudemire J, et al. Recombinant human interleukin-11 (rh-IL-11) stimulates megakaryocyte maturation and increase in peripheral platelet number in vivo. Blood 1991; 78: 518A
   Google Scholar
• Gordon M S, McCaskill-Stevens W J, Battiato L A, Loewy J, Loesch D, Breeden E, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 3615–3624
   PubMed Web of Science ®Google Scholar
• Orazi A, Cooper R J, Tong J, Gordon M S, Battiato L, Sledge G W, Jr, et al. Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol 1996; 24: 1289–1297
   PubMed Web of Science ®Google Scholar
• Isaacs C, Robert N J, Bailey F A, Schuster M W, Overmoyer B, Graham M, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15: 3368–3377
   PubMed Web of Science ®Google Scholar
• Tepler I, Elias L, Smith J W, II, Hussein M, Rosen G, Chang A Y, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 3607–3614
   PubMed Web of Science ®Google Scholar
• Cairo M S, Davenport V, Bessmertny O, Goldman S C, Berg S L, Kreissman S G, et al. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol 2005; 128: 49–58
   PubMed Web of Science ®Google Scholar
• Cripe L D, Rader K, Tallman M S, Gordon M S, Paietta E, Bennett J, et al. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. Leuk Res 2006; 30: 823–827
   PubMed Web of Science ®Google Scholar
• Matthews J P, Bishop J F, Young G A, Juneja S K, Lowenthal R M, Garson O M, et al. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. Br J Haematol 2001; 113: 727–736
   PubMed Web of Science ®Google Scholar
• Mitus A J, Miller K B, Schenkein D P, Ryan H F, Parsons S K, Wheeler C, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995; 13: 560–569
   PubMed Web of Science ®Google Scholar
• Antin J H, Smith B R, Holmes W, David R N, Rosenthal S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Inst Mitt 1988; 149–153
   PubMedGoogle Scholar
• Bessho M, Hirashima K, Asano S, Ikeda Y, Ogawa N, Tomonaga M, et al. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group. Eur J Haematol 1997; 58: 265–272
   PubMed Web of Science ®Google Scholar
• Saba H I. Myelodysplastic syndromes in the elderly: the role of growth factors in management. Leuk Res 1996; 20: 203–219
   PubMed Web of Science ®Google Scholar
• Bussel J B, Mukherjee R, Stone A J. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 2001; 66: 172–177
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Cortes J, Thomas D A, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001; 19: 4165–4172
   PubMed Web of Science ®Google Scholar
• Tsimberidou A M, Giles F J, Khouri I, Bueso-Ramos C, Pilat S, Thomas D A, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the MD. Anderson Cancer Center experience. Ann Oncol 2005; 16: 139–145
   PubMed Web of Science ®Google Scholar